10-hydroxycamptothecin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
10-hydroxycamptothecin
Accession Number
DB12385
Type
Small Molecule
Groups
Investigational
Description

10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-107124
Categories
UNII
9Z01632KRV
CAS number
19685-09-7
Weight
Average: 364.357
Monoisotopic: 364.105921623
Chemical Formula
C20H16N2O5
InChI Key
HAWSQZCWOQZXHI-FQEVSTJZSA-N
InChI
InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
IUPAC Name
(19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
SMILES
CC[[email protected]@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=CC1=C3)C2=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of 10-hydroxycamptothecin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 10-hydroxycamptothecin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of 10-hydroxycamptothecin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with 10-hydroxycamptothecin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 10-hydroxycamptothecin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of 10-hydroxycamptothecin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C17939
PubChem Compound
97226
PubChem Substance
347828633
ChemSpider
87754
BindingDB
50008922
ChEBI
81395
ChEMBL
CHEMBL273862

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.331 mg/mLALOGPS
logP1.69ALOGPS
logP0.92ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.65ChemAxon
pKa (Strongest Basic)3.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.96 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity96.47 m3·mol-1ChemAxon
Polarizability37.51 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTOF , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0009000000-7740e8a79502c7590530
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0009000000-acb0fc91e1e6144e4dfb
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0006-0009000000-1435843a0ba5003a7004
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-0493000000-f0b1c94385d0a4241330

Taxonomy

Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Hydroxyquinolines / Pyranopyridines / Pyridinones / 1-hydroxy-2-unsubstituted benzenoids / Tertiary alcohols / Heteroaromatic compounds / Carboxylic acid esters / Lactams / Lactones / Azacyclic compounds
show 7 more
Substituents
Camptothecin / Hydroxyquinoline / Pyranopyridine / Quinoline / 1-hydroxy-2-unsubstituted benzenoid / Pyridinone / Pyridine / Benzenoid / Heteroaromatic compound / Tertiary alcohol
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyranoindolizinoquinoline (CHEBI:81395)

Drug created on October 20, 2016 16:10 / Updated on November 09, 2017 05:06